Hepatitis C, Cirrhosis, and Chronic Liver Listings

Hepatitis C qualifies for Social Security Disability Insurance when chronic infection damages the liver enough to meet Blue Book Listing 5.05, the SSA listing for chronic liver disease, or when fatigue and other symptoms reduce your capacity to work below the substantial gainful activity level. A positive hepatitis C test by itself is not enough. The Social Security Administration (SSA) approves claims based on documented complications of advanced liver disease, staged from laboratory abnormalities to life-threatening bleeding.

SSA defines chronic liver disease (CLD) in Section 5.00C1 of the Blue Book as loss of liver function with cell death, inflammation, or scarring that persists for more than 6 months. The agency specifically names chronic hepatitis C virus infection as one of the common causes of CLD in adults, alongside chronic hepatitis B and prolonged alcohol abuse. Adjudicators evaluate jaundice, changes in the size of the liver and spleen, ascites, peripheral edema, and altered mental status, plus symptoms like itching, fatigue, nausea, loss of appetite, and sleep disturbances.

Stage One: Compensated Cirrhosis and the Laboratory Route

Many people with hepatitis C feel well for years while silent scarring progresses. For claims at this stage, the main listing pathway is Listing 5.05G, which turns four routine blood tests into a single number. The SSA CLD score is calculated from serum creatinine, total bilirubin, and International Normalized Ratio (INR), with serum sodium added when the initial calculation exceeds 11.

To meet Listing 5.05G, you need two SSA CLD scores of at least 20, each within a consecutive 12-month period and at least 60 days apart. All laboratory values used in one score must fall within a continuous 30-day period, and SSA publishes an official SSA CLD Calculator to compute the result. If both qualifying scores exist, SSA finds the impairment meets the listing from at least the date of the first score.

The formula rewards consistency in recordkeeping rather than dramatic single events. Liver biopsy results can support the diagnosis of CLD under Section 5.00C1b, but SSA states it will not purchase a liver biopsy. Your existing hepatology records, including serial lab panels, carry the claim at this stage.

Stage Two: Fluid Buildup in the Abdomen and Chest

Decompensated cirrhosis often announces itself with fluid. Listing 5.05B covers ascites, a pathologic accumulation of fluid in the peritoneal cavity, or hydrothorax, fluid in the pleural space around the lungs. Section 5.00C2b explains that the most common causes are portal hypertension and low serum albumin from CLD.

The listing requires the fluid to be present on two evaluations within a consecutive 12-month period, at least 60 days apart, and not attributable to other causes such as congestive heart failure or cancer. Each evaluation must document the fluid by paracentesis, by thoracentesis, or by imaging or physical examination combined with either a serum albumin of 3.0 g/dL or less or an INR of at least 1.5. Emergency room records and abdominal ultrasounds are often enough to build this timeline.

Stage Three: Bleeding From Varices and Portal Hypertension

Cirrhosis raises pressure in the portal venous system, which can rupture dilated veins in the esophagus or stomach. Listing 5.05A covers hemorrhaging from esophageal, gastric, or ectopic varices or from portal hypertensive gastropathy, documented by imaging, that produces two things. First, hemodynamic instability shown by signs such as pallor, profuse perspiration, rapid pulse, low blood pressure, postural hypotension, or fainting. Second, hospitalization for transfusion of at least 2 units of blood.

SSA then considers you disabled for 1 year following the documented transfusion, after which the agency reevaluates the residual impairment. Section 5.00C2a stresses that this one-year clock governs reevaluation, not the onset date of disability. If gastrointestinal hemorrhaging stems from a cause other than CLD, SSA evaluates it under Listing 5.02, which requires three transfusions of at least 2 units each within a consecutive 12-month period and at least 30 days apart.

Stage Four: Organ Failure Syndromes

Four separate criteria in Listing 5.05 address advanced complications, and each replaces guesswork with a measurable threshold.

Spontaneous Bacterial Peritonitis (5.05C)

This acute infection of peritoneal fluid is documented by a neutrophil count of at least 250 cells/mm3 on laboratory analysis of fluid obtained by paracentesis. Section 5.00C2c states that a single qualifying evaluation satisfies the criterion.

Hepatorenal Syndrome (5.05D)

Kidney failure arising from liver disease, with no underlying kidney pathology, meets the listing when documented by a serum creatinine of at least 2 mg/dL, urine output under 500 mL in 24 hours, or urine sodium below 10 mEq per liter.

Hepatopulmonary Syndrome (5.05E)

Arterial deoxygenation from intrapulmonary vascular dilation can be shown one of two ways. An arterial blood gas drawn at rest on room air must show a PaO2 at or below 60 mm Hg at test sites below 3,000 feet, 55 mm Hg from 3,000 through 6,000 feet, or 50 mm Hg above 6,000 feet. Alternatively, contrast-enhanced echocardiography or a macroaggregated albumin lung perfusion scan can show intrapulmonary arteriovenous shunting. Section 5.00C2e(ii) notes SSA will not purchase these specialized imaging studies but will obtain existing results.

Hepatic Encephalopathy (5.05F)

Confusion, delirium, stupor, or abnormal behavior from liver disease must appear on two evaluations at least 60 days apart within a 12-month period, combined with either a history of a TIPS or other surgical portosystemic shunt, or one of the following on two evaluations at least 60 days apart: asterixis (the characteristic flapping tremor), an EEG showing triphasic slow wave activity, serum albumin of 3.0 g/dL or less, or an INR of 1.5 or greater.

Transplantation and Compassionate Allowances

Listing 5.09 provides that a person who receives a liver transplant is considered disabled for 1 year from the date of transplant, after which SSA evaluates residual function, rejection episodes, and treatment complications. Onset of disability is determined from the facts of the case, as Section 5.00G explains.

Certain end-stage liver complications also appear on SSA's Compassionate Allowances list, including hepatorenal syndrome, hepatopulmonary syndrome, and hepatocellular carcinoma, the primary cancer that chronic hepatitis C can cause. Compassionate Allowances status speeds identification of the claim at intake, although eligibility still depends on medical documentation. Liver cancer itself is evaluated under the malignant neoplastic disease listings in Section 13.00.

Treatment History and the Fallback Analysis

Listing 5.05 does not contain an adherence-to-treatment clause like the one in Listing 5.08, which evaluates weight loss due to any digestive disorder despite adherence to prescribed medical treatment. Section 5.00H states that when there is no record of ongoing treatment, SSA assesses severity from the current evidence, and a person may still qualify through medical equivalence or residual functional capacity. Direct-acting antiviral cures have changed hepatitis C care, but documented decompensation events and laboratory damage remain in the record and support the claim.

Under Section 5.00J, if your impairment does not meet or medically equal a listing, SSA proceeds to assess residual functional capacity and the later steps of the sequential evaluation in 20 CFR 404.1520. Fatigue, malnutrition, and cognitive fog from encephalopathy legitimately limit standing, walking, and concentration.

Non-Medical Requirements in 2026

Medical criteria are only half of the analysis. You must be insured for disability under 20 CFR 404.130, which for most adults means 20 work credits in the 10 years ending with the onset of disability. In 2026, one work credit is earned for each $1,890 in covered wages, up to four credits per year. You must also avoid substantial gainful activity under 20 CFR 404.1574, capped in 2026 at $1,690 in average monthly earnings for non-blind claimants and $2,830 for claimants who are statutorily blind. The impairment must be expected to last at least 12 continuous months under 20 CFR 404.1509. Claim filing procedures and appeals follow separate rules outside the scope of this article.

Frequently Asked Questions

Is a hepatitis C diagnosis alone enough to qualify for SSDI? No. SSA evaluates hepatitis C as chronic liver disease under Listing 5.05 only when it produces specific complications such as variceal bleeding, recurrent ascites, or two qualifying SSA CLD scores of at least 20.

What is the SSA CLD score in Listing 5.05G? It is a laboratory calculation using serum creatinine, total bilirubin, INR, and sometimes serum sodium. Two scores of at least 20, drawn at least 60 days apart within a consecutive 12-month period, satisfy the listing.

Does curing hepatitis C with antiviral treatment affect a disability claim? A sustained cure does not erase documented decompensated cirrhosis, because Listing 5.05 does not require adherence to treatment the way other digestive listings do. Residual damage is evaluated on the current medical evidence.

This article provides general information about SSDI eligibility for liver disease, not legal advice. Program rules, medical listings, and dollar thresholds change over time, and all figures cited here reflect federal standards in effect in 2026. Consult a qualified representative or contact the Social Security Administration directly about your specific claim.